Drug Manufacturing

OSR Holdings, SillaJen sign MoU to pursue drug development

Global healthcare holding company OSR Holdings has entered into a memorandum of understanding (MoU) with SillaJen, a South Korea-based biotechnology company with a pipeline of immuno-oncology drug candidates.

AGC completes facility expansion for pDNA and mRNA production line

AGC Biologics has completed the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at Heidelberg, Germany.

Wheeler Bio launches drug substance CGMP facility in Oklahoma City

A biomanufacturing firm Wheeler Bio has launched a drug substance current good manufacturing practices (CGMP) facility in Oklahoma City, US.

Cell therapy CDMO Kincell Bio launches with $36m infusion

Kincell Bio, a cell therapy contract development and manufacturing organisation (CDMO) spun out of Inceptor Bio, has launched with $36m investment with an aim to help early-stage innovators develop and manufacture cell therapies.

Biovian to expand Turku manufacturing unit with $55m investment

Contract development and manufacturing organisation (CDMO) Biovian has announced plans to make an investment worth more than $55m (€50m) to expand its manufacturing facility at Turku in Finland.

Samsung Biologics, Pfizer partner for biosimilars portfolio manufacturing

Samsung Biologics has announced a strategic collaboration with Pfizer for the long-term commercial manufacturing of the latter’s multi-product biosimilars portfolio.

NICE recommends Cara’s Kapruvia to treat CKD-associated pruritus

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) have announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia (difelikefalin) to treat chronic kidney disease (CKD)-associated pruritus.

Melinta, Xediton partner to commercialise anti-infective products in Canada

Melinta Therapeutics and Xediton Pharmaceuticals have entered an exclusive commercialisation and licensing agreement for four novel anti-infective products.

FDA completes inspection of Nexus’ manufacturing facility in US

The Food and Drug Administration (FDA) has successfully inspected Nexus Pharmaceuticals’ pharmaceutical manufacturing facility located in Pleasant Prairie, Wisconsin, US.